Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| 10x Genomics, Inc.TXG · Entity 2172 | Director | September 22, 2026 | September 24, 2026 |
| Alector, Inc.ALEC · Entity 6051 | President and COO | December 10, 2021 | December 15, 2021 |
| Theravance Biopharma, Inc.TBPH · Entity 5037 | SVP, Corp Dev & Strategy | February 20, 2019 | February 22, 2019 |
| Ultragenyx Pharmaceutical Inc.RARE · Entity 4337 | Director | May 14, 2026 | May 18, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
10x Genomics, Inc.
Report date September 22, 2026 · Filed September 24, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Class A Common StockSEC Table I · non-derivative | Direct | 23,792 |
Ending reported balance
After 2026-09-22 transaction · row 5
5 source rows · reconciled sequenceRow 1 · 2026-09-22 · Sale · Disposed 292 · Balance 29,223 F1: The transaction reported herein was effected pursuant to the Reporting Person's Rule 10b5-1 trading plan, adopted on March 13, 2026. F2: This transaction was executed in multiple trades at prices ranging from $77.76 to $78.74, inclusive. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. Row 2 · 2026-09-22 · Sale · Disposed 614 · Balance 28,609 F1: The transaction reported herein was effected pursuant to the Reporting Person's Rule 10b5-1 trading plan, adopted on March 13, 2026. F3: This transaction was executed in multiple trades at prices ranging from $79.075 to $80.07, inclusive. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. Row 3 · 2026-09-22 · Sale · Disposed 1,325 · Balance 27,284 F1: The transaction reported herein was effected pursuant to the Reporting Person's Rule 10b5-1 trading plan, adopted on March 13, 2026. F4: This transaction was executed in multiple trades at prices ranging from $80.08 to $81.0769, inclusive. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. Row 4 · 2026-09-22 · Sale · Disposed 2,270 · Balance 25,014 F1: The transaction reported herein was effected pursuant to the Reporting Person's Rule 10b5-1 trading plan, adopted on March 13, 2026. F5: This transaction was executed in multiple trades at prices ranging from $81.08 to $82.0791, inclusive. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. Row 5 · 2026-09-22 · Sale · Disposed 1,222 · Balance 23,792 F1: The transaction reported herein was effected pursuant to the Reporting Person's Rule 10b5-1 trading plan, adopted on March 13, 2026. F6: This transaction was executed in multiple trades at prices ranging from $82.08 to $82.56, inclusive. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. |
Filing footnotes · ownership attribution and instrument terms
F1: The transaction reported herein was effected pursuant to the Reporting Person's Rule 10b5-1 trading plan, adopted on March 13, 2026.
F2: This transaction was executed in multiple trades at prices ranging from $77.76 to $78.74, inclusive. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.
F3: This transaction was executed in multiple trades at prices ranging from $79.075 to $80.07, inclusive. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.
F4: This transaction was executed in multiple trades at prices ranging from $80.08 to $81.0769, inclusive. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.
F5: This transaction was executed in multiple trades at prices ranging from $81.08 to $82.0791, inclusive. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.
F6: This transaction was executed in multiple trades at prices ranging from $82.08 to $82.56, inclusive. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.
Alector, Inc.
Report date December 10, 2021 · Filed December 15, 2021
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 102,598 |
Ending reported balance
After 2021-12-13 transaction · row 6
6 source rows · reconciled sequenceRow 1 · 2021-12-10 · Exercise / conversion · Acquired 75,000 · Balance 177,598 Row 2 · 2021-12-10 · Sale · Disposed 66,126 · Balance 111,472 F1: The sale reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan. F2: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $21.18 to $22.155, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (2) through (5) to this Form 4. Row 3 · 2021-12-10 · Sale · Disposed 8,874 · Balance 102,598 F1: The sale reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan. F3: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $22.205 to $22.54, inclusive. Row 4 · 2021-12-13 · Exercise / conversion · Acquired 75,000 · Balance 177,598 Row 5 · 2021-12-13 · Sale · Disposed 64,102 · Balance 113,496 F1: The sale reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan. F4: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $20.56 to $21.55, inclusive. Row 6 · 2021-12-13 · Sale · Disposed 10,898 · Balance 102,598 F1: The sale reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan. F5: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $21.565 to $21.92, inclusive. |
| Employee Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $17.23 · Expires 2029-12-31 | Direct | 380,187 |
Reported balance
After 2021-12-10 transaction · row 7
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 7 · 2021-12-10 · Exercise / conversion · Disposed 75,000 · Balance 380,187 F6: One-fourth of the shares subject to the option grant vested on December 9, 2020, and 1/48th vest monthly thereafter. |
| Employee Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $17.23 · Expires 2029-12-31 | Direct | 305,187 |
Reported balance
After 2021-12-13 transaction · row 8
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 8 · 2021-12-13 · Exercise / conversion · Disposed 75,000 · Balance 305,187 F6: One-fourth of the shares subject to the option grant vested on December 9, 2020, and 1/48th vest monthly thereafter. |
Filing footnotes · ownership attribution and instrument terms
F1: The sale reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan.
F2: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $21.18 to $22.155, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (2) through (5) to this Form 4.
F3: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $22.205 to $22.54, inclusive.
F4: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $20.56 to $21.55, inclusive.
F5: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $21.565 to $21.92, inclusive.
F6: One-fourth of the shares subject to the option grant vested on December 9, 2020, and 1/48th vest monthly thereafter.
Theravance Biopharma, Inc.
Report date February 20, 2019 · Filed February 22, 2019
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Ordinary SharesSEC Table I · non-derivative | Direct | 97,198 |
Reported balance
After 2019-02-20 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2019-02-20 · Tax withholding · Disposed 5,763 · Balance 97,198 F1: Includes 1,731 shares acquired under the Theravance Biopharma, Inc. 2013 Employee Share Purchase Plan on May 15, 2018. |
Filing footnotes · ownership attribution and instrument terms
F1: Includes 1,731 shares acquired under the Theravance Biopharma, Inc. 2013 Employee Share Purchase Plan on May 15, 2018.
Ultragenyx Pharmaceutical Inc.
Report date May 14, 2026 · Filed May 18, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 27,951 |
Ending reported balance
After 2026-05-18 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2026-05-14 · Grant · Acquired 7,751 · Balance 33,691 F1: Award of Restricted Stock Units ("RSUs") under the Company's 2023 Incentive Plan. The RSUs shall vest in full on the earlier of (i) the Company's next Annual Meeting of Stockholders or (ii) May 14, 2027. Row 2 · 2026-05-18 · Sale · Disposed 5,740 · Balance 27,951 |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $25.80 · Expires 2036-05-14 | Direct | 14,058 |
Reported balance
After 2026-05-14 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2026-05-14 · Grant · Acquired 14,058 · Balance 14,058 F2: The option shall vest in full on the earlier of (i) the Company's next Annual Meeting of Stockholders or (ii) May 14, 2027. |
Filing footnotes · ownership attribution and instrument terms
F1: Award of Restricted Stock Units ("RSUs") under the Company's 2023 Incentive Plan. The RSUs shall vest in full on the earlier of (i) the Company's next Annual Meeting of Stockholders or (ii) May 14, 2027.
F2: The option shall vest in full on the earlier of (i) the Company's next Annual Meeting of Stockholders or (ii) May 14, 2027.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| September 22, 2026 Filed Sep 24, 2026 20:30 UTC | 10x Genomics, Inc. TXG · Entity 2172 | SaleClass A Common Stock | 1,222 | $82.28 | $100,542.25 |
DisclosureSEC source: 0001610717-26-000422 · form4.xml · nonDerivative · entry 5 SULIMAN SHEHNAAZ · CIK 0001713070 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 23,792 F1 · kind: The transaction reported herein was effected pursuant to the Reporting Person's Rule 10b5-1 trading plan, adopted on March 13, 2026. F6 · price: This transaction was executed in multiple trades at prices ranging from $82.08 to $82.56, inclusive. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. Read SEC document |
| September 22, 2026 Filed Sep 24, 2026 20:30 UTC | 10x Genomics, Inc. TXG · Entity 2172 | SaleClass A Common Stock | 2,270 | $81.67 | $185,390.67 |
DisclosureSEC source: 0001610717-26-000422 · form4.xml · nonDerivative · entry 4 SULIMAN SHEHNAAZ · CIK 0001713070 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 25,014 F1 · kind: The transaction reported herein was effected pursuant to the Reporting Person's Rule 10b5-1 trading plan, adopted on March 13, 2026. F5 · price: This transaction was executed in multiple trades at prices ranging from $81.08 to $82.0791, inclusive. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. Read SEC document |
| September 22, 2026 Filed Sep 24, 2026 20:30 UTC | 10x Genomics, Inc. TXG · Entity 2172 | SaleClass A Common Stock | 1,325 | $80.82 | $107,081.73 |
DisclosureSEC source: 0001610717-26-000422 · form4.xml · nonDerivative · entry 3 SULIMAN SHEHNAAZ · CIK 0001713070 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 27,284 F1 · kind: The transaction reported herein was effected pursuant to the Reporting Person's Rule 10b5-1 trading plan, adopted on March 13, 2026. F4 · price: This transaction was executed in multiple trades at prices ranging from $80.08 to $81.0769, inclusive. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. Read SEC document |
| September 22, 2026 Filed Sep 24, 2026 20:30 UTC | 10x Genomics, Inc. TXG · Entity 2172 | SaleClass A Common Stock | 614 | $79.51 | $48,820.00 |
DisclosureSEC source: 0001610717-26-000422 · form4.xml · nonDerivative · entry 2 SULIMAN SHEHNAAZ · CIK 0001713070 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 28,609 F1 · kind: The transaction reported herein was effected pursuant to the Reporting Person's Rule 10b5-1 trading plan, adopted on March 13, 2026. F3 · price: This transaction was executed in multiple trades at prices ranging from $79.075 to $80.07, inclusive. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. Read SEC document |
| September 22, 2026 Filed Sep 24, 2026 20:30 UTC | 10x Genomics, Inc. TXG · Entity 2172 | SaleClass A Common Stock | 292 | $78.20 | $22,833.20 |
DisclosureSEC source: 0001610717-26-000422 · form4.xml · nonDerivative · entry 1 SULIMAN SHEHNAAZ · CIK 0001713070 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 29,223 F1 · kind: The transaction reported herein was effected pursuant to the Reporting Person's Rule 10b5-1 trading plan, adopted on March 13, 2026. F2 · price: This transaction was executed in multiple trades at prices ranging from $77.76 to $78.74, inclusive. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. Read SEC document |
| August 24, 2026 Filed Aug 26, 2026 20:42 UTC | 10x Genomics, Inc. TXG · Entity 2172 | SaleClass A Common Stock | 1,646 | $63.97 | $105,288.69 |
DisclosureSEC source: 0001610717-26-000389 · form4.xml · nonDerivative · entry 2 SULIMAN SHEHNAAZ · CIK 0001713070 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 29,515 F1 · kind: The transaction reported herein was effected pursuant to the Reporting Person's Rule 10b5-1 trading plan, adopted on March 13, 2026. F3 · price: This transaction was executed in multiple trades at prices ranging from $63.42 to $64.29, inclusive. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. Read SEC document |
| August 24, 2026 Filed Aug 26, 2026 20:42 UTC | 10x Genomics, Inc. TXG · Entity 2172 | SaleClass A Common Stock | 561 | $62.73 | $35,189.23 |
DisclosureSEC source: 0001610717-26-000389 · form4.xml · nonDerivative · entry 1 SULIMAN SHEHNAAZ · CIK 0001713070 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 31,161 F1 · kind: The transaction reported herein was effected pursuant to the Reporting Person's Rule 10b5-1 trading plan, adopted on March 13, 2026. F2 · price: This transaction was executed in multiple trades at prices ranging from $62.26 to $63.23, inclusive. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. Read SEC document |
| June 16, 2026 Filed Jun 18, 2026 20:08 UTC | 10x Genomics, Inc. TXG · Entity 2172 | SaleClass A Common Stock | 364 | $33.27 | $12,111.66 |
DisclosureSEC source: 0001610717-26-000242 · form4.xml · nonDerivative · entry 2 SULIMAN SHEHNAAZ · CIK 0001713070 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 31,722 F1 · kind: The transaction reported herein was effected pursuant to the Reporting Person's Rule 10b5-1 trading plan, adopted on March 13, 2026. F3 · price: This transaction was executed in multiple trades at prices ranging from $33.03 to $33.49, inclusive. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. Read SEC document |
| June 16, 2026 Filed Jun 18, 2026 20:08 UTC | 10x Genomics, Inc. TXG · Entity 2172 | SaleClass A Common Stock | 5,359 | $32.59 | $174,644.45 |
DisclosureSEC source: 0001610717-26-000242 · form4.xml · nonDerivative · entry 1 SULIMAN SHEHNAAZ · CIK 0001713070 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 32,086 F1 · kind: The transaction reported herein was effected pursuant to the Reporting Person's Rule 10b5-1 trading plan, adopted on March 13, 2026. F2 · price: This transaction was executed in multiple trades at prices ranging from $32.03 to $33.02, inclusive. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. Read SEC document |
| June 04, 2026 Filed Jun 8, 2026 23:26 UTC | 10x Genomics, Inc. TXG · Entity 2172 | GrantClass A Common Stock | 8,829 | $0.00 | $0.00 |
DisclosureSEC source: 0001610717-26-000195 · form4.xml · nonDerivative · entry 1 SULIMAN SHEHNAAZ · CIK 0001713070 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 37,445 F1 · shares: Constitute restricted stock units ("RSUs"). Each RSU represents a contingent right to receive one share of Class A Common Stock upon vesting. 1/4th of the RSUs shall vest on each quarterly anniversary measured from May 21, 2026, subject to the Reporting Person continuing as a service provider through each such date. Read SEC document |
| May 18, 2026 Filed May 18, 2026 22:41 UTC | Ultragenyx Pharmaceutical Inc. RARE · Entity 4337 | SaleCommon Stock | 5,740 | $25.12 | $144,188.80 |
DisclosureSEC source: 0001713070-26-000002 · ownership.xml · nonDerivative · entry 2 SULIMAN SHEHNAAZ · CIK 0001713070 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 27,951 Read SEC document |
| May 14, 2026 Filed May 18, 2026 22:41 UTC | Ultragenyx Pharmaceutical Inc. RARE · Entity 4337 | GrantStock Option (Right to Buy) · Derivative | 14,058 | $0.00 Strike: $25.80 | $0.00 |
DisclosureSEC source: 0001713070-26-000002 · ownership.xml · derivative · entry 3 SULIMAN SHEHNAAZ · CIK 0001713070 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 14,058 Underlying: Common Stock · 14,058 shares Expires 2036-05-14 F2 · derivative.exercise_date: The option shall vest in full on the earlier of (i) the Company's next Annual Meeting of Stockholders or (ii) May 14, 2027. Read SEC document |
| May 14, 2026 Filed May 18, 2026 22:41 UTC | Ultragenyx Pharmaceutical Inc. RARE · Entity 4337 | GrantCommon Stock | 7,751 | $0.00 | $0.00 |
DisclosureSEC source: 0001713070-26-000002 · ownership.xml · nonDerivative · entry 1 SULIMAN SHEHNAAZ · CIK 0001713070 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 33,691 F1 · shares: Award of Restricted Stock Units ("RSUs") under the Company's 2023 Incentive Plan. The RSUs shall vest in full on the earlier of (i) the Company's next Annual Meeting of Stockholders or (ii) May 14, 2027. Read SEC document |
| June 03, 2025 Filed Jun 5, 2025 21:22 UTC | 10x Genomics, Inc. TXG · Entity 2172 | GrantClass A Common Stock | 15,357 | $0.00 | $0.00 |
DisclosureSEC source: 0001610717-25-000171 · form4.xml · nonDerivative · entry 1 SULIMAN SHEHNAAZ · CIK 0001713070 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 28,616 F1 · shares: Constitute restricted stock units ("RSUs"). Each RSU represents a contingent right to receive one share of Class A Common Stock upon vesting. 1/4th of the RSUs shall vest on each quarterly anniversary measured from May 21, 2025, subject to the Reporting Person continuing as a service provider through each such date. Read SEC document |
| May 15, 2025 Filed May 19, 2025 22:34 UTC | Ultragenyx Pharmaceutical Inc. RARE · Entity 4337 | GrantStock Option (Right to Buy) · Derivative | 10,787 | $0.00 Strike: $34.84 | $0.00 |
DisclosureSEC source: 0000950170-25-074669 · ownership.xml · derivative · entry 2 SULIMAN SHEHNAAZ · CIK 0001713070 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 10,787 Underlying: Common Stock · 10,787 shares Expires 2035-05-15 F2 · derivative.exercise_date: The option shall vest in full on the earlier of (i) the Company's next Annual Meeting of Stockholders or (ii) May 15, 2026. Read SEC document |
| May 15, 2025 Filed May 19, 2025 22:34 UTC | Ultragenyx Pharmaceutical Inc. RARE · Entity 4337 | GrantCommon Stock | 5,740 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-25-074669 · ownership.xml · nonDerivative · entry 1 SULIMAN SHEHNAAZ · CIK 0001713070 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 25,940 F1 · shares: Award of Restricted Stock Units ("RSUs") under the Company's 2023 Incentive Plan. The RSUs shall vest in full on the earlier of (i) the Company's next Annual Meeting of Stockholders or (ii) May 15, 2026. Read SEC document |
| June 18, 2024 Filed Jun 20, 2024 18:22 UTC | Ultragenyx Pharmaceutical Inc. RARE · Entity 4337 | GrantStock Option (Right to Buy) · Derivative | 9,900 | $0.00 Strike: $37.42 | $0.00 |
DisclosureSEC source: 0000950170-24-075483 · ownership.xml · derivative · entry 2 SULIMAN SHEHNAAZ · CIK 0001713070 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 9,900 Underlying: Common Stock · 9,900 shares Expires 2034-06-18 F2 · derivative.exercise_date: The option shall vest in full on the earlier of (i) the Company's next Annual Meeting of Stockholders or (ii) June 18, 2025. Read SEC document |
| June 18, 2024 Filed Jun 20, 2024 18:22 UTC | Ultragenyx Pharmaceutical Inc. RARE · Entity 4337 | GrantCommon Stock | 5,345 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-24-075483 · ownership.xml · nonDerivative · entry 1 SULIMAN SHEHNAAZ · CIK 0001713070 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 20,200 F1 · shares: Award of Restricted Stock Units ("RSUs") under the Company's 2023 Incentive Plan. The RSUs shall vest in full on the earlier of (i) the Company's next Annual Meeting of Stockholders or (ii) June 18, 2025. Read SEC document |
| June 11, 2024 Filed Jun 13, 2024 20:23 UTC | 10x Genomics, Inc. TXG · Entity 2172 | GrantClass A Common Stock | 8,649 | $0.00 | $0.00 |
DisclosureSEC source: 0001610717-24-000327 · form4.xml · nonDerivative · entry 1 SULIMAN SHEHNAAZ · CIK 0001713070 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 13,259 F1 · shares: Constitute restricted stock units ("RSUs"). Each RSU represents a contingent right to receive one share of Class A Common Stock upon vesting. 1/4th of the RSUs shall vest on each quarterly anniversary measured from May 21, 2024, subject to the Reporting Person continuing as a service provider through each such date. Read SEC document |
| June 14, 2023 Filed Jun 16, 2023 21:43 UTC | 10x Genomics, Inc. TXG · Entity 2172 | GrantStock Option (right to buy) · Derivative | 4,661 | $0.00 Strike: $57.62 | $0.00 |
DisclosureSEC source: 0001610717-23-000176 · form4.xml · derivative · entry 2 SULIMAN SHEHNAAZ · CIK 0001713070 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 4,661 Underlying: Class A Common Stock · 4,661 shares Expires 2033-06-14 F2 · derivative.exercise_date: 1/12th of the total number of shares subject to the option vest on each monthly anniversary measured from June 14, 2023, subject to the Reporting Person continuing as a service provider through each such date. Read SEC document |
| June 14, 2023 Filed Jun 16, 2023 21:43 UTC | 10x Genomics, Inc. TXG · Entity 2172 | GrantClass A Common Stock | 1,865 | $0.00 | $0.00 |
DisclosureSEC source: 0001610717-23-000176 · form4.xml · nonDerivative · entry 1 SULIMAN SHEHNAAZ · CIK 0001713070 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 4,610 F1 · shares: Constitute restricted stock units ("RSUs"). Each RSU represents a contingent right to receive one share of Class A Common Stock upon vesting. 1/4th of the RSUs shall vest on each quarterly anniversary measured from May 21, 2023, subject to the Reporting Person continuing as a service provider through each such date. Read SEC document |
| June 07, 2023 Filed Jun 9, 2023 18:30 UTC | Ultragenyx Pharmaceutical Inc. RARE · Entity 4337 | GrantStock Option (Right to Buy) · Derivative | 7,110 | $0.00 Strike: $51.82 | $0.00 |
DisclosureSEC source: 0001209191-23-035689 · doc4.xml · derivative · entry 2 SULIMAN SHEHNAAZ · CIK 0001713070 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 7,110 Underlying: Common Stock · 7,110 shares Expires 2033-06-07 F2 · derivative.exercise_date: The option shall vest in full on the earlier of (i) the Company's next Annual Meeting of Stockholders or (ii) June 7, 2024. Read SEC document |
| June 07, 2023 Filed Jun 9, 2023 18:30 UTC | Ultragenyx Pharmaceutical Inc. RARE · Entity 4337 | GrantCommon Stock | 3,860 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-035689 · doc4.xml · nonDerivative · entry 1 SULIMAN SHEHNAAZ · CIK 0001713070 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 14,855 F1 · shares: Award of Restricted Stock Units ("RSUs") under the Company's 2014 Incentive Plan. The RSUs shall vest in full on the earlier of (i) the Company's next Annual Meeting of Stockholders or (ii) June 7, 2024. Read SEC document |
| June 24, 2022 Filed Jun 28, 2022 17:48 UTC | Ultragenyx Pharmaceutical Inc. RARE · Entity 4337 | GrantStock Option (Right to Buy) · Derivative | 6,245 | $0.00 Strike: $60.57 | $0.00 |
DisclosureSEC source: 0001209191-22-039562 · doc4.xml · derivative · entry 2 SULIMAN SHEHNAAZ · CIK 0001713070 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,245 Underlying: Common Stock · 6,245 shares Expires 2032-06-24 F2 · derivative.exercise_date: The option shall vest in full on the earlier of (i) the Company's next Annual Meeting of Stockholders or (ii) June 24, 2023. Read SEC document |
| June 24, 2022 Filed Jun 28, 2022 17:48 UTC | Ultragenyx Pharmaceutical Inc. RARE · Entity 4337 | GrantCommon Stock | 3,300 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-22-039562 · doc4.xml · nonDerivative · entry 1 SULIMAN SHEHNAAZ · CIK 0001713070 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,995 F1 · shares: Award of Restricted Stock Units ("RSUs") under the Company's 2014 Incentive Plan. The RSUs shall vest in full on the earlier of (i) the Company's next Annual Meeting of Stockholders or (ii) June 24, 2023. Read SEC document |
| June 15, 2022 Filed Jun 17, 2022 21:16 UTC | 10x Genomics, Inc. TXG · Entity 2172 | GrantStock Option (right to buy) · Derivative | 5,300 | $0.00 Strike: $39.62 | $0.00 |
DisclosureSEC source: 0001567619-22-013120 · doc1.xml · derivative · entry 2 SULIMAN SHEHNAAZ · CIK 0001713070 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,300 Underlying: Class A Common Stock · 5,300 shares Expires 2032-06-15 F2 · derivative.exercise_date: This option, granted pursuant to the Issuer's 2019 Omnibus Incentive Plan, vests as to one-twelfth of the shares on July 15, 2022 and each month thereafter, subject to the Reporting Person continuing as a service provider through each such date. Read SEC document |
| June 15, 2022 Filed Jun 17, 2022 21:16 UTC | 10x Genomics, Inc. TXG · Entity 2172 | GrantClass A Common Stock | 2,120 | $0.00 | $0.00 |
DisclosureSEC source: 0001567619-22-013120 · doc1.xml · nonDerivative · entry 1 SULIMAN SHEHNAAZ · CIK 0001713070 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,745 F1 · shares: These securities are restricted stock units ("RSUs"). Each RSU represents a contingent right to receive one share of Class A Common Stock. One-fourth of the RSUs, granted pursuant to the Issuer's 2019 Omnibus Incentive Plan, shall vest on August 21, 2022 and on each three-month anniversary thereafter, subject to the Reporting Person continuing as a service provider through each such date. Read SEC document |
| December 13, 2021 Filed Dec 15, 2021 01:23 UTC | Alector, Inc. ALEC · Entity 6051 | Exercise / conversionEmployee Stock Option (right to buy) · Derivative | 75,000 | $0.00 Strike: $17.23 | $0.00 |
DisclosureSEC source: 0001209191-21-069643 · doc4.xml · derivative · entry 8 SULIMAN SHEHNAAZ · CIK 0001713070 · President and COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 305,187 Underlying: Common Stock · 75,000 shares Expires 2029-12-31 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F6 · derivative.exercise_date: One-fourth of the shares subject to the option grant vested on December 9, 2020, and 1/48th vest monthly thereafter. Read SEC document |
| December 13, 2021 Filed Dec 15, 2021 01:23 UTC | Alector, Inc. ALEC · Entity 6051 | SaleCommon Stock | 10,898 | $21.73 | $236,801.55 |
DisclosureSEC source: 0001209191-21-069643 · doc4.xml · nonDerivative · entry 6 SULIMAN SHEHNAAZ · CIK 0001713070 · President and COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 102,598 F1 · kind: The sale reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan. F5 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $21.565 to $21.92, inclusive. Read SEC document |
| December 13, 2021 Filed Dec 15, 2021 01:23 UTC | Alector, Inc. ALEC · Entity 6051 | SaleCommon Stock | 64,102 | $21.16 | $1,356,347.04 |
DisclosureSEC source: 0001209191-21-069643 · doc4.xml · nonDerivative · entry 5 SULIMAN SHEHNAAZ · CIK 0001713070 · President and COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 113,496 F1 · kind: The sale reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan. F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $20.56 to $21.55, inclusive. Read SEC document |
| December 13, 2021 Filed Dec 15, 2021 01:23 UTC | Alector, Inc. ALEC · Entity 6051 | Exercise / conversionCommon Stock | 75,000 | $17.23 | $1,292,250.00 |
DisclosureSEC source: 0001209191-21-069643 · doc4.xml · nonDerivative · entry 4 SULIMAN SHEHNAAZ · CIK 0001713070 · President and COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 177,598 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| December 10, 2021 Filed Dec 15, 2021 01:23 UTC | Alector, Inc. ALEC · Entity 6051 | Exercise / conversionEmployee Stock Option (right to buy) · Derivative | 75,000 | $0.00 Strike: $17.23 | $0.00 |
DisclosureSEC source: 0001209191-21-069643 · doc4.xml · derivative · entry 7 SULIMAN SHEHNAAZ · CIK 0001713070 · President and COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 380,187 Underlying: Common Stock · 75,000 shares Expires 2029-12-31 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F6 · derivative.exercise_date: One-fourth of the shares subject to the option grant vested on December 9, 2020, and 1/48th vest monthly thereafter. Read SEC document |
| December 10, 2021 Filed Dec 15, 2021 01:23 UTC | Alector, Inc. ALEC · Entity 6051 | SaleCommon Stock | 8,874 | $22.33 | $198,191.92 |
DisclosureSEC source: 0001209191-21-069643 · doc4.xml · nonDerivative · entry 3 SULIMAN SHEHNAAZ · CIK 0001713070 · President and COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 102,598 F1 · kind: The sale reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $22.205 to $22.54, inclusive. Read SEC document |
| December 10, 2021 Filed Dec 15, 2021 01:23 UTC | Alector, Inc. ALEC · Entity 6051 | SaleCommon Stock | 66,126 | $21.69 | $1,433,975.37 |
DisclosureSEC source: 0001209191-21-069643 · doc4.xml · nonDerivative · entry 2 SULIMAN SHEHNAAZ · CIK 0001713070 · President and COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 111,472 F1 · kind: The sale reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $21.18 to $22.155, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (2) through (5) to this Form 4. Read SEC document |
| December 10, 2021 Filed Dec 15, 2021 01:23 UTC | Alector, Inc. ALEC · Entity 6051 | Exercise / conversionCommon Stock | 75,000 | $17.23 | $1,292,250.00 |
DisclosureSEC source: 0001209191-21-069643 · doc4.xml · nonDerivative · entry 1 SULIMAN SHEHNAAZ · CIK 0001713070 · President and COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 177,598 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| December 09, 2021 Filed Dec 11, 2021 00:20 UTC | Alector, Inc. ALEC · Entity 6051 | Exercise / conversionEmployee Stock Option (right to buy) · Derivative | 75,000 | $0.00 Strike: $17.23 | $0.00 |
DisclosureSEC source: 0001209191-21-069130 · doc4.xml · derivative · entry 10 SULIMAN SHEHNAAZ · CIK 0001713070 · President and COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 455,187 Underlying: Common Stock · 75,000 shares Expires 2029-12-31 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F7 · derivative.exercise_date: One-fourth of the shares subject to the option grant vested on December 9, 2020, and 1/48th vest monthly thereafter. Read SEC document |
| December 09, 2021 Filed Dec 11, 2021 00:20 UTC | Alector, Inc. ALEC · Entity 6051 | SaleCommon Stock | 2,643 | $23.40 | $61,857.56 |
DisclosureSEC source: 0001209191-21-069130 · doc4.xml · nonDerivative · entry 7 SULIMAN SHEHNAAZ · CIK 0001713070 · President and COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 102,598 F2 · kind: The sale reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan. F6 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $23.36 to $23.44, inclusive. Read SEC document |
| December 09, 2021 Filed Dec 11, 2021 00:20 UTC | Alector, Inc. ALEC · Entity 6051 | SaleCommon Stock | 72,357 | $22.80 | $1,649,985.61 |
DisclosureSEC source: 0001209191-21-069130 · doc4.xml · nonDerivative · entry 6 SULIMAN SHEHNAAZ · CIK 0001713070 · President and COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 105,241 F2 · kind: The sale reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan. F5 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $22.36 to $23.35, inclusive. Read SEC document |
| December 09, 2021 Filed Dec 11, 2021 00:20 UTC | Alector, Inc. ALEC · Entity 6051 | Exercise / conversionCommon Stock | 75,000 | $17.23 | $1,292,250.00 |
DisclosureSEC source: 0001209191-21-069130 · doc4.xml · nonDerivative · entry 5 SULIMAN SHEHNAAZ · CIK 0001713070 · President and COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 177,598 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| December 08, 2021 Filed Dec 11, 2021 00:20 UTC | Alector, Inc. ALEC · Entity 6051 | Exercise / conversionEmployee Stock Option (right to buy) · Derivative | 55,187 | $0.00 Strike: $10.24 | $0.00 |
DisclosureSEC source: 0001209191-21-069130 · doc4.xml · derivative · entry 9 SULIMAN SHEHNAAZ · CIK 0001713070 · President and COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 134,026 Underlying: Common Stock · 55,187 shares Expires 2030-09-30 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F8 · derivative.exercise_date: The shares subject to the option vest in 48 equal monthly installments beginning on November 1, 2020. Read SEC document |
| December 08, 2021 Filed Dec 11, 2021 00:20 UTC | Alector, Inc. ALEC · Entity 6051 | Exercise / conversionEmployee Stock Option (right to buy) · Derivative | 19,813 | $0.00 Strike: $17.23 | $0.00 |
DisclosureSEC source: 0001209191-21-069130 · doc4.xml · derivative · entry 8 SULIMAN SHEHNAAZ · CIK 0001713070 · President and COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 530,187 Underlying: Common Stock · 19,813 shares Expires 2029-12-31 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F7 · derivative.exercise_date: One-fourth of the shares subject to the option grant vested on December 9, 2020, and 1/48th vest monthly thereafter. Read SEC document |
| December 08, 2021 Filed Dec 11, 2021 00:20 UTC | Alector, Inc. ALEC · Entity 6051 | SaleCommon Stock | 38,489 | $23.01 | $885,689.62 |
DisclosureSEC source: 0001209191-21-069130 · doc4.xml · nonDerivative · entry 4 SULIMAN SHEHNAAZ · CIK 0001713070 · President and COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 102,598 F2 · kind: The sale reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan. F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $22.94 to $23.10, inclusive. Read SEC document |
| December 08, 2021 Filed Dec 11, 2021 00:20 UTC | Alector, Inc. ALEC · Entity 6051 | SaleCommon Stock | 36,511 | $22.56 | $823,626.09 |
DisclosureSEC source: 0001209191-21-069130 · doc4.xml · nonDerivative · entry 3 SULIMAN SHEHNAAZ · CIK 0001713070 · President and COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 141,087 F2 · kind: The sale reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $21.94 to $22.92, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (2) through (6) to this Form 4. Read SEC document |
| December 08, 2021 Filed Dec 11, 2021 00:20 UTC | Alector, Inc. ALEC · Entity 6051 | Exercise / conversionCommon Stock | 55,187 | $10.24 | $565,114.88 |
DisclosureSEC source: 0001209191-21-069130 · doc4.xml · nonDerivative · entry 2 SULIMAN SHEHNAAZ · CIK 0001713070 · President and COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 177,598 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| December 08, 2021 Filed Dec 11, 2021 00:20 UTC | Alector, Inc. ALEC · Entity 6051 | Exercise / conversionCommon Stock | 19,813 | $17.23 | $341,377.99 |
DisclosureSEC source: 0001209191-21-069130 · doc4.xml · nonDerivative · entry 1 SULIMAN SHEHNAAZ · CIK 0001713070 · President and COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 122,411 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · balance_after: Includes 755 shares acquired on December 1, 2020 and 1,843 shares acquired on June 1, 2021 pursuant to the Issuer's employee stock purchase plan. Read SEC document |
| June 24, 2021 Filed Jun 28, 2021 22:22 UTC | Ultragenyx Pharmaceutical Inc. RARE · Entity 4337 | GrantStock Option (Right to Buy) · Derivative | 4,125 | $0.00 Strike: $93.20 | $0.00 |
DisclosureSEC source: 0001209191-21-043535 · doc4.xml · derivative · entry 2 SULIMAN SHEHNAAZ · CIK 0001713070 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,125 Underlying: Common Stock · 4,125 shares Expires 2031-06-24 F2 · derivative.exercise_date: The option shall vest in full on the earlier of (i) the Company's next Annual Meeting of Stockholders or (ii) June 24, 2022. Read SEC document |
| June 24, 2021 Filed Jun 28, 2021 22:22 UTC | Ultragenyx Pharmaceutical Inc. RARE · Entity 4337 | GrantCommon Stock | 2,145 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-21-043535 · doc4.xml · nonDerivative · entry 1 SULIMAN SHEHNAAZ · CIK 0001713070 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,695 F1 · shares: Award of Restricted Stock Units ("RSUs") under the Company's 2014 Incentive Plan. The RSUs shall vest in full on the earlier of (i) the Company's next Annual Meeting of Stockholders or (ii) June 24, 2022. Read SEC document |
| June 11, 2021 Filed Jun 15, 2021 21:54 UTC | 10x Genomics, Inc. TXG · Entity 2172 | GrantStock Option (right to buy) · Derivative | 1,563 | $0.00 Strike: $193.51 | $0.00 |
DisclosureSEC source: 0001209191-21-040697 · doc4.xml · derivative · entry 2 SULIMAN SHEHNAAZ · CIK 0001713070 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,563 Underlying: Class A Common Stock · 1,563 shares Expires 2031-06-11 F2 · derivative.exercise_date: This option, granted pursuant to the Issuer's 2019 Omnibus Incentive Plan, vests as to one-twelfth of the shares on July 11, 2021 and each month thereafter, subject to the Reporting Person continuing as a service provider through each such date. Read SEC document |
| June 11, 2021 Filed Jun 15, 2021 21:54 UTC | 10x Genomics, Inc. TXG · Entity 2172 | GrantClass A Common Stock | 625 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-21-040697 · doc4.xml · nonDerivative · entry 1 SULIMAN SHEHNAAZ · CIK 0001713070 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 625 F1 · shares: These securities are restricted stock units ("RSUs"). Each RSU represents a contingent right to receive one share of Class A Common Stock. One-fourth of the RSUs, granted pursuant to the Issuer's 2019 Omnibus Incentive Plan, shall vest on August 21, 2021 and on each three-month anniversary thereafter, subject to the Reporting Person continuing as a service provider through each such date. Read SEC document |
| May 07, 2021 Filed May 11, 2021 22:34 UTC | Alector, Inc. ALEC · Entity 6051 | GrantCommon Stock | 100,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-21-031839 · doc4.xml · nonDerivative · entry 1 SULIMAN SHEHNAAZ · CIK 0001713070 · President and COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 100,000 F1 · shares: The reported shares are represented by performance share units, or PSUs. Fifty percent of the award will be earned if the Issuer's average closing stock price is $30 per share for 40 consecutive trading days and an additional fifty percent will be earned if the average closing stock price is $40 per share for 40 consecutive trading days. Upon attainment of the performance metrics, the shares vest in four equal quarterly installments beginning on the first vesting date as set forth in the PSU award agreement. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.